Triazole Resistance Is Still Not Emerging in Aspergillus fumigatus Isolates Causing Invasive Aspergillosis in Brazilian Patients
Nenhuma Miniatura disponível
Data
2017
Autores
Negri, Clara E. [UNIFESP]
Goncalves, Sarah S.
Sousa, Ana Cristina P. [UNIFESP]
Bergamasco, Maria Daniela [UNIFESP]
Martino, Marines D. V.
Queiroz-Telles, Flavio
Aquino, Valerio Rodrigues
Castro, Paulo de Tarso O.
Hagen, Ferry
Meis, Jacques F.
Orientadores
Tipo
Artigo
Título da Revista
ISSN da Revista
Título de Volume
Resumo
Aspergillus fumigatus azole resistance has emerged as a global health problem. We evaluated the in vitro antifungal susceptibility of 221 clinical A. fumigatus isolates according to CLSI guidelines. Sixty-one isolates exhibiting MICs at the epidemiological cutoff value (ECV) for itraconazole or above the ECV for any triazole were checked for CYP51A mutations. No mutations were documented, even for the isolates (1.8%) with high voriconazole MICs, indicating that triazoles may be used safely to treat aspergillosis in Brazil.
Descrição
Citação
Antimicrobial Agents And Chemotherapy. Washington, v. 61, n. 11, p. -, 2017.